APIMEDS PHARMACEUTICALS US, INC. Capital Expenditures
APIMEDS PHARMACEUTICALS US, INC. (APUS) reported Capital Expenditures of $9.39 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquirePropertyPlantAndEquipment · last filed 2026-08-14
- APIMEDS PHARMACEUTICALS US, INC. payments to acquire property, plant, and equipment for the quarter ending 2026-06-30 was $0.00.
- APIMEDS PHARMACEUTICALS US, INC. payments to acquire property, plant, and equipment for the quarter ending 2026-03-31 was $9.39K.
- APIMEDS PHARMACEUTICALS US, INC. payments to acquire property, plant, and equipment for the quarter ending 2025-12-31 was $21.42K.
- APIMEDS PHARMACEUTICALS US, INC. payments to acquire property, plant, and equipment for the quarter ending 2025-09-30 was $22.54K.
- APIMEDS PHARMACEUTICALS US, INC. payments to acquire property, plant, and equipment for fiscal 2025 was $57.33K.
| Period end | Payments to Acquire Property, Plant, and Equipment 3 month | Payments to Acquire Property, Plant, and Equipment 6 month | Payments to Acquire Property, Plant, and Equipment 9 month | Payments to Acquire Property, Plant, and Equipment 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $9.39K 10-Q · filed 2026-08-14 | $30.82K derived: sum of 3 quarters · filed 2026-08-14 | $53.36K derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $9.39K 10-Q · filed 2026-05-26 | $30.82K derived: sum of 2 quarters · filed 2026-05-26 | $53.36K derived: sum of 3 quarters · filed 2026-05-26 | |
| 2025-12-31 | $21.42K derived: 10-K 12 month − 10-Q 9 month · filed 2026-05-04 | $43.96K derived: sum of 2 quarters · filed 2026-05-04 | $57.33K 10-K · filed 2026-05-04 | |
| 2025-09-30 | $22.54K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $35.91K 10-Q · filed 2025-11-12 | ||
| 2025-06-30 | $13.37K 10-Q · filed 2026-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |